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Abstract
Background and aims: The autonomic nervous system 
(ANS) is capable of modulating pain. Aberrations in heart 
rate variability (HRV), reflective of ANS activity, are asso-
ciated with experimental pain sensitivity, chronic pain, 
and more recently, pain modulatory mechanisms but the 
underlying mechanisms are still unclear. HRV is lowered 
during experimental pain as well as in chronic pain con-
ditions and HRV can be increased by propranolol, which 
is a non-selective β-blocker. Sensitization of central pain 
pathways have been observed in several chronic pain 
conditions and human mechanistic pain biomarkers for 
these central pain pathways include temporal summation 
of pain (TSP) and conditioned pain modulation (CPM). 
The current study aimed to investigate the effect of the 
β-blocker propranolol, and subsequently assessing the 
response to standardized, quantitative, mechanistic pain 
biomarkers.
Methods: In this placebo-controlled, double-blinded, 
randomized crossover study, 25  healthy male volunteers 
(mean age 25.6 years) were randomized to receive 40 mg 
propranolol and 40  mg placebo. Heart rate, blood pres-
sure, and HRV were assessed before and during experi-
mental pain tests. Cuff pressure pain stimulation was 
used for assessment of pain detection (cPDTs) and pain 
tolerance (cPTTs) thresholds, TSP, and CPM. Offset anal-
gesia (OA) was assessed using heat stimulation.
Results: Propranolol significantly reduced heart rate 
(p < 0.001), blood pressure (p < 0.02) and increased HRV 
(p < 0.01) compared with placebo. No significant dif-
ferences were found comparing cPDT (p > 0.70), cPTT 
(p > 0.93), TSP (p > 0.70), OA-effect (p > 0.87) or CPM 
(p > 0.65) between propranolol and placebo.
Conclusions: The current study demonstrated that pro-
pranolol increased HRV, but did not affect pressure 
pain sensitivity or any pain facilitatory or modulatory 
outcomes.
Implications: Analgesic effects of propranolol have been 
reported in clinical pain populations and the results from 
the current study could indicate that increased HRV from 
propranolol is not associated with peripheral and central 
pain pathways in healthy male subjects.
Keywords: β-blockers; heart rate variability; conditioned 
pain modulation; offset analgesia; temporal summation 
of pain; pressure pain threshold.
1   Introduction
Propranolol is a non-selective β-blocker originally used to 
treat portal hypertension [1], but has also been applied as 
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an anxiolytic [2] and migraine prophylactic [3]. Proprano-
lol exerts its antihypertensive effects by blocking both the 
β-1 (resulting in a reduction of cardiac output and splanch-
nic blood flow) and β-2 (resulting in splanchnic vasocon-
striction due to unopposed activation of adrenergic α-1 
receptors) receptors [4]. In addition, propranolol has 
indirect-acting parasympathomimetic effects, whereby 
it increases heart rate variability (HRV) [5] – a common 
measure of the relative contributions of parasympathetic 
activity in the autonomic control of the heart.
Low HRV has been proposed as a marker for cardio-
vascular diseases [6–8] and accumulating evidence sug-
gests a close relationship between the autonomic nervous 
system (ANS) and pain processing [9–11], where HRV is 
found lowered during experimental pain as well as in 
chronic pain conditions [9, 12]. Furthermore, reduced HRV 
has also been associate with increased pain in fibromy-
algia [13], and increased post-surgical pain [14]. Adminis-
tration of propranolol has been shown to alleviate pain 
in fibromyalgia [15], and temporomandibular joint dis-
order (TMD) [16]. In addition, propranolol can minimize 
opioid-induced mechanical and thermal hyperalgesia 
[17], indicating that propranolol can modulate periph-
eral and central pain pathways. Administration of Cat-
echol-O-methyltransferase inhibitors in rodents produces 
increased pain sensitivity at multiple body sites [18, 19], 
but this pain sensitivity can be blocked by administration 
of the nonselective β-adrenergic receptor antagonists such 
propranolol [19, 20]. Likewise, intramuscular injection 
of serotonin in humans generates pain [21], which again 
can be reduced by co-administration of propranolol [22]. 
There are several mechanisms of which propranolol could 
mediate the analgesic effects such as peripheral blocking 
of the β-2-receptors [20, 23], or by blocking of the serotonin 
receptors in the central nervous system [24]. In spite of the 
evidence implicating ANS activity and in pain processing 
and the clinical usefulness of propranolol, it is unknown 
whether pain facilitatory and modulatory mechanisms are 
affected by ANS output under normal conditions.
Pain inhibition is commonly assessed using condi-
tioned pain modulation (CPM), which is a proxy measure 
of the balance between descending pain inhibition and 
facilitation in humans [25]. CPM is functional in healthy 
subjects, but impaired in several chronic pain conditions 
such as osteoarthritis [26], fibromyalgia [27] and chronic 
pancreatic pain [28]. Recently, offset analgesia (OA) has 
been suggested as another measure of descending pain 
inhibition [29] and is observed as a disproportionally 
reduction in perceived pain following a slight decrease in 
painful stimulus intensity [30]. OA has been suggested to 
act via different pain pathways than CPM [31, 32], but the 
specific pathways of OA are largely unknown [29]. Patients 
with neuropathic pain display impairments in both OA 
[33] and CPM [34]. Temporal summation of pain (TSP) is 
considered a measure of the mechanisms responsible for 
pain facilitation in the central nervous system and has 
been found associated with pain progression [35–37]. The 
potential role of the ANS in the modulation of central pain 
processing is unclear, and studies have yet to investigate 
the effect of pharmacologically augmented parasympa-
thomimetic activity on pain sensitivity, TSP, OA, or CPM.
The aim of this study was to investigate the effect of 
propranolol on CPM, with secondary outcome measures 
being experimental pain assessments such as pressure pain 
thresholds, TSP, and OA. We hypothesized that propranolol 
would increase HRV and in turn decrease pain sensitivity.
2   Methods
2.1   Study design
The study used a randomized, placebo-controlled, dou-
ble-blinded, crossover design, with the two experimen-
tal sessions being separated by at least 1 week. A single 
40 mg dose of propranolol was used as a drug model of 
parasympathomimetic activation. An identical looking 
capsule (containing 40  mg calcium) was administrated 
as placebo. On each study day, the subjects were admin-
istered either propranolol or placebo in a randomized 
order. The experimental assessments were conducted 2 h 
after administration, corresponding to the expected peak 
plasma concentration of propranolol [38]. The experi-
mental sequence for pain assessments was: pressure pain 
thresholds, TSP, OA, and CPM. HRV was recorded prior to 
and during the CPM testing in each session.
2.2   Participants
Izumi et al. [39] found a CPM effect of 12 kPa (SD: 10 kPa) 
and this study was designed to find a change in CPM of 
at least 75%, with a power of 80% with a significant level 
of 0.05, why 25 healthy men, mean age 25.6 (range: 20–
37) years, were recruited from July 2016 to January 2017. 
Participants were excluded if they suffered from any con-
comitant pain conditions, used any analgesics, lacked 
understanding of the procedures, had any history of 
alcohol or drug misuse, were diagnosed with cardio-vas-
cular diseases, asthma, diabetes, or had known decreased 
function of the liver or kidneys. All participants were given 
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oral and written information and signed written informed 
consent prior to the initiation of the study. The study com-
plied with the Helsinki Declaration, was approved by the 
local Ethical Committee (reference number: N-20120043), 
and registered at ClinicalTrials.gov (registration number: 
NCT02808611).
2.3   Cardiovascular and heart rate variability 
measures
Blood pressure was recorded with subjects relaxing in a 
supine position for 5 min before the commencement of the 
experimental tests using the Omron Automatic Blood Pres-
sure Monitor, Model: M3 (Imron Healthcare, Kyoto, Japan). 
Heart rate and HRV were assessed using a Polar RS800CX 
heart rate monitor (Polar Electro, Kempele, Finland) and 
all measurements were recorded for 5 min. An elastic chest 
band with built-in recording electrodes (wetted before use) 
was placed horizontally immediately below the papilla 
mammaria. The Polar RS800CX has been used in a number 
of empirical investigations, and is reliable for assessments 
in a supine position at rest [40]. The device records inter-
beat intervals (IBI) at a sampling frequency of 1,000  Hz, 
providing a temporal resolution of 1 ms for each R–R inter-
val. Timestamps were inserted for the baseline recordings 
(prior to experimental tests) and during CPM paradigms. 
The following time-domain measures were derived from 
analysis in Kubios HRV: mean IBI (ms), the square root of 
the mean squared difference of successive R–R intervals 
(rMSSD, ms), and the percentage of adjacent cycles that 
are greater than 50 ms apart (pNN50, %), which is in line 
with previous studies in this field [41–43]. Measures from 
the frequency-domain were not analysis, since they have 
recently been heavily criticized. Both rMSSD and pNN50 
reflect vagal-parasympathetic activity [9].
2.4   Sudomotor activity
Skin conductance measurements were performed by gal-
vanic skin resistance measurements with a DermaLab 
USB Hydration eight-pin probe (Cortex Technology ApS, 
Hadsund, Denmark), as a measure of sudomotor activ-
ity and a proxy for sympathetic activity in the ANS. The 
probe was gently wiped off in a cotton cloth before each 
assessment. Measurements were performed in duplicate 
on the index and middle fingers and an average was used 
for statistical analysis. Skin conductance was assessed 
before the experimental tests and 30  s after cuff or CPT 
conditioned pain in according with a previous study [41].
2.5   Experimental pain assessments
2.5.1   Pressure pain thresholds
Pressure stimulation was applied by a computer-con-
trolled cuff algometer (Cortex Technology ApS, Hadsund, 
Denmark and Aalborg University, Aalborg, Denmark). A 
13 cm wide air-cuff (VBM, Sulz am Neckar, Germany) was 
wrapped around the belly of the gastrocnemius muscle, 
centering approximately at the level of the lower leg with 
the maximum circumference, and was inflated at a rate 
of 1 kPa/s. The participants were instructed to rate the 
pain intensity of the cuff pressure stimulus on a handheld 
10  cm computerized VAS where zero denotes “no pain”, 
and 10 denotes “worst imaginable pain”. The pressure at 
VAS = 1 was defined as cuff pressure pain detection thresh-
old (cPDT) [44, 45], and the pressure at which participants 
felt the pain became intolerable was defined as the pres-
sure pain tolerance threshold (cPTT).
2.5.2   Temporal summation of pain
Ten identical pressure stimuli, equivalent to a pressure at 
individual cPTT-level, with 1 s duration and 1 s inter-stim-
ulus interval, were applied to induce TSP. Subjects were 
asked to rate their pain intensity continuously during 
sequential stimulation on the VAS. In addition, subjects 
were instructed not to return the VAS to zero in-between 
the 10  stimulations. The VAS score after each stimulus 
were extracted, as commonly done when assessing TSP 
using cuff algometry [46–48]. For analysis of TSP, the 
mean VAS score was calculated in the interval from the 
first to the end of the fourth stimulus (VAS-I) and in the 
interval from the eighth to the end of the 10th stimulus 
(VAS-II). Temporal summation of pain was defined as the 
difference between VAS-I and VAS-II (i.e. VAS-II minus 
VAS-I), which is commonly used when assessing TSP 
using cuff algometry [46, 47].
2.5.3   Offset analgesia
Heat stimulations were applied using the Pathway Neu-
rosensory Analyzer (Medoc ltd., Ramat Yishai, Israel) 
and the ATS 30 × 30  mm squared probe. First, a constant 
control stimulus of 48 °C was applied to the dorsal forearm 
for 30 s. After a short break, the offset analgesia paradigm 
was applied in three intervals T1 (5 s), T2 (5 s), and T3 (20 s) 
with temperatures during the trials selected as follows: 
T1 = 48 °C, T2 = 49 °C, and T3 = 48 °C. The subjects were 
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asked to assess the pain of the thermal stimuli using the 
electronic VAS (VAS0−10 with 0 = “no pain” and 10 = “worst 
imaginable pain”). The analgesic effects have been docu-
mented to take place after the decrease of the tempera-
ture from T2 to T3 (49 °C–48 °C) [30, 49]. The average pain 
ratings following the decrease from T2 to T3, i.e. in the time 
interval between 16 s and 20 s (due to the delay of the ther-
modes to reach the target temperature and the responses 
latency) were calculated. The window-time used for statis-
tical analysis of OA-effect was adapted based on previous 
studies [30, 49].
2.5.4   Conditioned pain modulation
CPM was measured using two protocols for test stimuli (TS) 
and two conditioning stimuli (CS). cPDT was applied as the 
TS on the dominant leg and one protocol applied 70% of 
cPTT as CS on the non-dominant leg while the other pro-
tocol applied the cold pressor test as CS where the subjects 
were instructed to immerse the non-dominant hand up 
to the wrist into the stirred ice-cold water (0–4 °C). The 
subjects were allowed to withdraw their hand from the 
ice-water if it became too painful, but were instructed re-
immerse their hand and aim the pain rating for approxi-
mately VAS = 7, which has previously been applied in 
comparable studies [50, 51]. Both CS were applied for 5 min 
to allow for the HRV measures to be conducted.
The CPM-effect was calculated as the differences in 
pressure needed to evoke cPDT while conditioned sub-
tracted from cPDT at baseline (unconditioned). A 15 min 
break was included between the two CPM tests to avoid 
carry-over effects [52]. Subjects completed both CPM pro-
tocols that were randomized in order. Pain ratings from 
both cuff and CPT conditioned stimuli were recorded.
2.5.5   Statistical analysis
All values are presented as mean and standard error of 
mean (±SEM) if not otherwise indicated. Visual inspection 
confirmed normal distribution of data. Data were tested 
for normality using QQ-plots and the Kolmogorov-Smirnov 
normality test. The rMSSD data were log-transforms to 
achieve normality.
The effects of propranolol compared to placebo 
on ANS activity and sensory tests were analysis using 
repeated measures analysis of variance (rm-ANOVA) 
with drug (propranolol, placebo) as the main factor. 
For OA, the paradigm (constant, OA-paradigm) factor 
was added to investigate the difference in pain rating 
from a constant 48 °C stimulus to a OA-paradigm. For 
CPM, a  paradigm (cPDTbaseline, cPDTconditioned) factor was 
added to investigate the inhibitory response from a 
baseline cPDT to cPDT during a conditioned stimuli. To 
 investigate changes in HRV measures during the con-
ditioned stimuli, a time (baseline, during conditioned) 
factor was added for both CPT and tonic cuff condition-
ing stimuli.
The statistical analyses were performed by SPSS 
(version 23, IBM Corporation, NY, USA). p-Values 
<0.05 were considered as significant.
3   Results
3.1   The effect of propranolol on heart rate 
and blood pressure
Propranolol significantly reduced heart rate (F(1,24) = 25.89, 
p < 0.001) as well as diastolic and systolic blood pressure 
(F(1,24) = 6.89, p = 0.015) compared with placebo (Table 1). 
No adverse event were observed.
3.1.1   Pressure pain sensitivity
No statistical drug effect was found for cPDT (F(1,24) = 0.15, 
p = 0.70) or cPTT (F(1,24) = 0.01, p = 0.93) when comparing 
propranolol to placebo, indicating that propranolol did 
not influence pressure pain sensitivity (Fig. 1).
Table 1: Mean and standard deviation (SD) of heart rate and blood pressure measures 2 h after administration of propranolol or placebo in 
25 healthy male subjects.
Propranolol Placebo Effect size (Cohen’s d)
Heart rate (beats/min) 55.99 (SD: 6.21)a 61.64 (SD: 7.30) 1.96
Blood pressure (systolic/diastolic, mmHg) 112.04/68.44a (SD: 13.42/9.42) 116.08/70.28 (SD: 10.81/7.71) 0.53/0.21
The effect size was calculated using Cohen’s d. mmHg = millimeter of mercury. aIndicate p < 0.05 comparing propranolol to placebo.
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3.1.2   Temporal summation of pain
The rm-ANOVA showed no difference in TSP comparing 
propranolol and placebo (F(1,24) = 0.16, p = 0.70), indicating 
that propranolol did not influence pain facilitation in the 
central nervous system (Fig. 2).
3.1.3   Offset analgesia
A significantly decreased pain rating was found for the 
OA-paradigm compared with the baseline-paradigm 
(F(1,24) = 15.70, p = 0.001), indicative of functional OA in 
the study sample. No significant drug effect was found 
(F(1,24) = 0.03, p = 0.87), indicating that propranolol did not 
affect offset pain modulation (Fig. 3).
3.1.4   Conditioned pain modulation
Pain ratings to CPT (mean VAS: 6.65, SEM: 0.29) was sig-
nificantly increased compared with cuff (mean VAS: 6.06, 
SEM: 0.27) conditioning stimuli (p = 0.048). cPDT signifi-
cantly increased during conditioning pain stimulation 
using both the CPT and a tonic cuff stimulus (rm-ANOVA: 
F(1,24) > 17.49, p < 0.001). There was no effect of drug (rm-
ANOVA: F(1,24) = 0.22, p = 0.65), signifying functional CPM 
was unaffected by propranolol (Fig. 4).
3.1.5   The effect of propranolol and tonic cuff and cold 
pressor test stimuli on the autonomic nervous 
system
A significant drug effect was found at baseline (prior to 
experimental tests), showing that compared to placebo, 
administration of propranolol resulted in a significantly 
increased mean IBI (F(1,24) = 28.85, p < 0.001, Fig. 5A), rMSSD 
(F(1,24) = 7.44, p = 0.01, Fig. 5B), and pNN50 (F(1,24) = 12.28, 
p = 0.002, Fig. 5C). There was no effect of propranolol on 
skin conductance (F(1,24) = 0.93, p = 0.34; Fig. 5D) compared 
with placebo prior to experimental tests.
Fig. 1: Cuff pressure detection (cPDT) and tolerance threshold 
(cPTT) assess on the (A) non-dominant and the (B) dominant lower 
leg assessed by cuff algometry for healthy males subjects following 
administration of propranolol and placebo.
Fig. 2: Temporal summation of pain for healthy male subjects 
administered propranolol and placebo. Temporal summation of pain 
was assessed by 10 identical pressure stimuli and the mean VAS score 
was calculated in the interval from the first to the end of the fourth 
stimulus (VAS-I) and in the interval from the eighth to the end of the 
tenth stimulus (VAS-II). Temporal summation of pain was defined as 
the difference between VAS-I and VAS-II.
Fig. 3: Pain rating to a constant 48 °C heat stimulus and to an offset 
analgesia (OA) paradigm applied to healthy males subjects after 
administration of either propranolol or placebo. *Indicates p < 0.05 
comparing the constant heat stimulus to the OA-paradigm.
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A significant time effect comparing ANS activity 
during CPT to baseline (prior to CPT), showed increased 
heart rate (F(1,24) = 8.71, p = 0.01), rMSSD (F(1,24) = 6.11, 
p = 0.021, Fig. 5B), and decreased mean IBI (F(1,24) = 8.70, 
p = 0.01, Fig. 5A). In addition, a significant time effect 
was seen for both cuff and CPT compared with  baseline 
(prior to cuff and CPT, respectively), which showed 
increased skin conductance (F(1,24) > 15.89, p < 0.005, 
 Fig. 5D).
4   Discussion
The present randomized, placebo-controlled, crossover 
study showed that propranolol exerts a parasympatho-
mimetic effect, decreasing heart rate and blood pressure, 
while increasing measures of vagally-mediated HRV, com-
pared to placebo. However, propranolol did not affect the 
quantitative, mechanistic pain biomarkers (pressure pain 
thresholds, temporal summation of pain, offset analgesia, 
or conditioned pain modulation) in healthy male volunteers.
4.1   Pain and the automatous system
The parasympathetic vagus nerve influences pain. 
For instance, vagotomy increases pain, and stimula-
tion of the vagus nerve reduces thermal pain sensitiv-
ity in both animal [53–55] and human [56, 57] studies. 
Afferent baroreceptor signaling has been suggested to 
modulate pain perception via medullary and mesen-
cephalic neural circuitry that modulates descending 
pain inhibition [58, 59]. Lowered parasympathetic activ-
ity has been associated with increased ratings of pain 
in response to thermal stimuli in healthy subjects [60, 
61], patients with fibromyalgia [62], and in patients 
Fig. 4: Unconditioned cuff pressure detection threshold (cPDT) and 
conditioned cPDT with (A) cuff algometry or (B) the cold pressor test 
(CPT). *Indicates p < 0.05 comparing conditioned cPDT to uncondi-
tioned cPDT.
Fig. 5: Measures of heart rate variability (A–C) and skin conductance (D) at baseline and during conditioning pain from cuff algometry and 
the cold pressor test (CPT). 
IBI, The mean inter beat interval; rMSSD, the root mean squared difference of successive R–R intervals; pNN50, the percentage of adjacent 
cycles that are greater than 50 ms apart. #Indicate p < 0.05 comparing propranolol to placebo and *indicate p < 0.05 comparing conditioning 
stimuli to baseline.
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with chemotherapy-induced polyneuropathy [63]. A 
recent study found propranolol to reduce measures of 
central sensitization in a migraine rat model [64] and 
two human experimental pain studies suggest that pro-
pranolol has potential antihyperalgesic effects although 
the mechanism(s) involved remain elusive or perhaps 
related to off-target interactions [17, 22] – a finding not 
supported by the present study. Transcutaneous-vagus 
nerve stimulation increases HRV [65] and have been 
found to increase mechanical and pressure pain thresh-
olds and reduce mechanical pain sensitivity [56] in 
healthy males and to reduced evoked pain intensity and 
TSP in patients with chronic pelvic pain [66].
Increase HRV can be achieved by other pharmaceuti-
cal approaches, such as Scopolamine [67, 68] or Atropine 
[69, 70], or non-pharmacological, such as transcutaneous-
vagus nerve stimulation [65] or deep breathing [71], and 
future studies could investigate if these have different 
effects on the central pain mechanisms investigated in the 
current study.
4.2   Pressure pain thresholds
Pain thresholds are commonly used to assess alterations 
in pain sensitivity following acute or chronic injury. 
However, pain thresholds exhibit high inter-individual 
variability, which is believed to be driven by factors such 
as genotype [72], sex [73], psychological state [74], and 
ANS activity [9]. Despite this, the intra-individual relia-
bility of pressure pain thresholds has been documented 
as good-to-excellent in studies assessing the intra- and 
inter-session [50, 75] reliability. Clinically, patients with 
chronic pain conditions such as osteoarthritis [26], 
migraine [76], or fibromyalgia [27] show lower pres-
sure pain thresholds compared to pain-free individuals. 
Therefore, understanding the variability related to pres-
sure pain threshold testing is critical for future clinical 
use. In this context, the ANS has been suggested to be 
associated with experimental pain outcomes, and some 
of the variance found in pain threshold testing [9]. The 
current study administrated a β-blocker, evoking an 
increased HRV, but found the β-blocker to have no effect 
on pressure pain detection or tolerance thresholds com-
pared with placebo. These results indicate that a small 
but significant increase in HRV does not alter pain sen-
sitivity in pain-free male subjects per se. Notably, pre-
vious studies have demonstrated that intramuscular 
propranolol provides an immediate analgesic response 
[22] to pain from intramuscular injection of serotonin 
[21]. However, the intramuscular injection of proprano-
lol in these studies may have resulted in a higher local 
concentration of propranolol, compared to the systemic 
(i.e. oral) administration used in the current study.
4.3   Central pain modulatory mechanisms
Temporal summation of pain assesses pain facilitation, 
while CPM and OA assess endogenous pain inhibition in 
humans [26]. For CPM, a functioning inhibitory system is 
commonly reported in healthy subjects, corresponding to 
a significant increase in the perceived intensity of a test 
stimulus during the delivery of a conditioning stimulus 
[77], similar to what was found in the current study. OA 
represents a disproportional reduction in perceived pain 
following a slight decrease in painful stimulus intensity 
in healthy subjects [30, 49], which the current study also 
demonstrated.
Administration of ketamine influences CPM but not 
OA [32]. Furthermore, differences in brain activity have 
been recorded during an OA and CPM paradigm [78], 
suggesting that the mechanisms underlying CPM and 
OA are different. A recent study found that increased 
HRV was associated with lower pain ratings during an 
offset analgesia paradigm [79], suggesting an associa-
tion between OA and the ANS. Nahman-Averbuch et al. 
[42] found that ANS activity in woman was associated 
with an OA-effect whereas ANS activity in men was 
associated with a CPM-effect, indicating sex-dependent 
effects, which should be investigated in future studies. 
It could be assumed that measures of ANS activity are 
associated with CPM, since afferent baroreceptor signals 
have been implicated in the modulation of pain percep-
tion via medullary and mesencephalic neural circuitry, 
influencing descending pain inhibition [58, 59] and med-
ullary transections, reducing diffuse noxious inhibitory 
control (the preclinical counterpart to CPM) in rats [80] 
– presenting promising avenues for future research in 
humans.  Schweinhardt et al. [81] investigated 39 healthy 
males and studied the effect of propranolol on heat 
pain sensitivity and a found small decreased effect size 
for propranolol compared with placebo, which could 
explain that the peripheral contribution of propranolol 
is limited, which could be an explanation for why OA 
did not change in the current study.
Maekawa et al. [82], compared infusion of proprano-
lol to saline and fond propranolol to lower heart rate at 
baseline and during CPT, which is similar to the IBI find-
ings from the current study.
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4.4   Limitations
The current study found an increase in HRV following 
propranolol administration but did not find this to be 
associated with differences in efficacy of any facilitatory 
or inhibitory pain mechanisms. Due to safety reasons, 
the current study administrated a low single-dose pro-
pranolol to healthy young males who showed normal 
heart rate and blood pressure. This could limit a potential 
effect of propranolol on central pain processing mecha-
nisms, rendering differences between propranolol and the 
placebo undetectable. Contrasting this, similar doses, as 
used in the current study, are used by students for exam-
related anxiety [83] and similar low doses have previously 
lowered pain ratings in patients with fibromyalgia and 
TMD [15]. Moreover, 40 mg represents the initial maximal 
recommend dosage for hypertension and tachycardia. 
Despite this, the current study did find effects on heart 
rate, blood pressure and HRV but no effect and central 
pain mechanism. It is unknown if more substantial para-
sympathomimetic effects would modulate pain process-
ing mechanisms in healthy subjects.
The most significant ANS responsiveness aberrations 
related to pain have been observed in chronic pain patients 
suffering from, e.g. fibromyalgia [15] or TMD [16] and are 
generally related to a decrease of parasympathetic resting 
activity. Prolonged suppression of parasympathetic activ-
ity is thus not necessarily reproducible in an acute design 
as applied in the present study. Several previous studies 
support an antihyperalgesic [23, 84] and a potential anal-
gesic [15, 16] effect of propranolol but the linkage between 
these effects is unclear. The present study did not employ an 
experimental model of evoked hyperalgesia such as intra-
dermal capsaicin [85], burn-injury or L-menthol [86] evoked 
secondary hyperalgesia and thus cannot corroborate previ-
ous finding related to propranolol-induced antihyperalgesia.
5   Conclusion
The current study found that propranolol decreased heart 
rate, blood pressure and increased HRV but had no impact 
on pain sensitivity or pain modulatory status in healthy 
male subjects.
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